key: cord-0270275-25u2obdc authors: Lapointe, H. R.; Mwimanzi, F.; Cheung, P. K.; Sang, Y.; Yaseen, F.; Kalikawe, R.; Datwani, S.; Waterworth, R.; Umviligihozo, G.; Ennis, S.; Young, L.; Dong, W.; Kirkby, D.; Burns, L.; Leung, V.; Holmes, D.; DeMarco, M. L.; Simons, J.; Matic, N.; Montaner, J. S. G.; Brumme, C. J.; Prystajecky, N.; Niikura, M.; Lowe, C. F.; Romney, M. G.; Brockman, M. A.; Brumme, Z. L. title: Serial infection with SARS-CoV-2 Omicron BA.1 and BA.2 following three-dose COVID-19 vaccination date: 2022-05-21 journal: nan DOI: 10.1101/2022.05.19.22275026 sha: 5d354a0337b4cd07efaedd802b43c60dc3e604ce doc_id: 270275 cord_uid: 25u2obdc SARS-CoV-2 Omicron infections are common among individuals who are vaccinated or have recovered from prior variant infection, but few reports have documented serial Omicron infections. We characterized SARS-CoV-2 humoral responses in a healthy young person who acquired laboratory-confirmed Omicron BA.1.15 ten weeks after a third dose of BNT162b2, and BA.2 thirteen weeks later. Responses were compared to those of 124 COVID-19 naive vaccinees. One month after the second and third vaccine doses, the participant's wild-type and BA.1-specific IgG, ACE2 competition and virus neutralization activities were average for a COVID-19 naive triple-vaccinated individual. BA.1 infection boosted the participant's responses to the cohort >95th percentile, but even this strong "hybrid" immunity failed to protect against BA.2. Moreover, reinfection increased BA.1 and BA.2-specific responses only modestly. Results illustrate the risk of Omicron infection in fully vaccinated individuals and highlight the importance of personal and public health measures as vaccine-induced immune responses wane. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 21, 2022. The participant was a frontline health care worker in their early 30s with no chronic health 148 conditions. They received three doses of mRNA vaccine (all BNT162b2; 30mcg) in late 149 December 2020, early February 2021 and late October 2021 ( Figure 1A ). All blood samples 150 collected up to one month following the third immunization were anti-N seronegative. 151 In early January 2022, ten weeks after the third immunization, the participant experienced 153 moderate symptoms including sore throat, fatigue, congestion, body aches, severe headaches, and mental fog, as well as severe long-term, treatment-resistant shortness of breath triggered by 168 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. We next characterized BA.2-specific Spike IgG and ACE2 competition activities in a subset of 235 participants (79% Female, median age 59 years) beginning one month following the third 236 vaccine dose ( Figure 2 ). As these analyses focus on whole Spike (rather than RBD antigen), the 237 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 21, 2022. corresponding wild-type and BA.1-specific responses are also shown for context (Figure 2) . We 238 additionally confirmed the (strong) correlations between wild-type-and BA.1-specific RBD and 239 Spike responses in these individuals (all p<0.0001; Figure S1 ). At one month post-third vaccine is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 21, 2022. ; https://doi.org/10.1101/2022.05.19.22275026 doi: medRxiv preprint Following BA.2 infection, the participant's wild-type Spike IgG concentration declined slightly 262 to 5.77 log10 U/mL, whereas their BA.1 and BA.2-specific values increased slightly to 5.25 and 263 5.56 log10 U/mL respectively (Figure 2A) . These trends were consistent with their wild-type-and 264 BA.1-specific RBD IgG concentrations (shown in Figure 1B) , though of a smaller magnitude. 265 Similar to the ACE2 competition activities measured using RBD antigens (shown in Figure 1C concluded that such events were rare (<0.1% of cases during the brief window of analysis) and 283 more likely to occur among unvaccinated individuals, but further evaluation of the data indicates 284 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. While it is perhaps unsurprising that COVID-19 vaccines based on ancestral SARS-CoV-2 304 sequences will not generate sterilizing immunity against Omicron strains that have evolved to 305 evade host immune responses (4, 38-42), various lines of evidence suggest that "hybrid" 306 immunity resulting from vaccination plus infection provides greater protection against SARS-307 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 21, 2022. ; https://doi.org/10.1101/2022.05.19.22275026 doi: medRxiv preprint CoV-2 variants (5, 43), due in part to maturation of Spike-specific antibodies (44-46) and 308 expansion of antiviral T cells (47-52). In light of this, we note that symptomatic BA.1 infection 309 boosted vaccine-induced humoral responses against both BA.1 and BA.2 in our case participant, 310 but the heightened response nevertheless failed to prevent subsequent symptomatic infection by 311 BA.2. Moreover, even after vaccination plus two Omicron infections, the participant's ACE2 312 competition and virus neutralization responses against BA.1 (as well as ACE2 competition 313 activity against BA.2) plateaued at levels substantially lower than those seen against the wild-314 type strain, suggesting that the participant will remain at risk of new Omicron infections. A 315 limitation of our study is that it did not assess T cell responses, which can reduce disease severity 316 but may have less impact on virus transmission (53, 54) , and thus we may be underestimating the 317 protection that results from infection and reinfection in this case. Indeed, the participant's 318 symptoms following both infections were not severe enough to require hospitalization, 319 demonstrating that vaccination was effective in its primary goal of preventing disease. Our 320 results nevertheless illustrate the potentially limited ability of current vaccines to prevent 321 recurrent infections and symptomatic disease caused by Omicron variants. 322 Sequences were submitted to GISAID. The raw data supporting the conclusions of this article 325 will be made available by the authors upon reasonable request. The DELTAS Africa Initiative is an independent funding scheme of the African Academy of 355 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The authors declare that the research was conducted in the absence of any commercial or 363 financial relationships that could be construed as a potential conflict of interest. 364 365 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted May 21, 2022. ; https://doi.org/10.1101/2022.05.19.22275026 doi: medRxiv preprint Increased Risk of Sars-Cov-2 Reinfection Associated with Emergence of Omicron in South 410 Impact of the Omicron 413 Variant on Sars-Cov-2 Reinfections in France 416 Protection against the Omicron Variant from Previous Sars-Cov-2 Infection Omicron 419 Extensively but Incompletely Escapes Pfizer Bnt162b2 Neutralization Protection by 422 Vaccines and Previous Infection against the Omicron Variant of Sars-Cov-2 Rapid 425 Increase in Sars-Cov-2 Seroprevalence During the Emergence of Omicron Variant Epub 20220428 Rapid 429 Emergence of Sars-Cov-2 Omicron Variant Is Associated with an Infection Advantage 430 over Delta in Vaccinated Persons Rapid 433 Epidemic Expansion of the Sars-Cov-2 Omicron Variant in Southern Africa BC Centre for Disease Control. Weekly Update on Variants of Concern Weekly Reporting of Covid-19 Cases, Hospitalizations Public Health Agency of Canada. Canadian Covid-19 Vaccination Coverage Report -29 Government of British Columbia. Get a Booster Dose -Province of British Columbia Covid News: Omicron Infected Half of British Columbians Almost Half of Canadians May Have Caught Covid Doctors Seeing Covid-19 Reinfection in Patients Who Recently Had 456 Sars-Cov-2 Convalescent Cohort Identified a Common Strategy for Escape of Vaccine-461 Induced Anti-Rbd Antibodies by Beta and Omicron Variants Omicron 464 Neutralizing Antibody Response Following Booster Vaccination Compared with 465 Breakthrough Infection. medRxiv (2022) Neutralizing Immunity in Vaccine Breakthrough Infections from the Sars-Cov-2 Omicron 469 and Delta Variants 472 Effectiveness of Bnt162b2 Vaccine Booster against Sars-Cov-2 Infection and 473 Breakthrough Complications Vaccine 476 Breakthrough Infection with the Sars-Cov-2 Delta or Omicron (Ba.1) Variant Leads Distinct Profiles of Neutralizing Antibody Responses. medRxiv Neutralizing Antibody 480 Responses Elicited by Sars-Cov-2 Mrna Vaccination Wane over Time and Are Breakthrough Infections with Sars-Cov-2 Omicron Despite Mrna Vaccine Booster Dose Occurrence and Significance of Omicron Ba.1 Infection Followed by Ba.2 Reinfection Reduced 490 Magnitude and Durability of Humoral Immune Responses to Covid-19 Mrna Vaccines 491 among Older Adults Adults Mount Less Durable Humoral Responses to Two Doses of Covid-19 Mrna Vaccine, 495 but Strong Initial Responses to a Third Dose Variants of Concern, Including B.1.1.28/P.1, British Columbia Viral Load among Nasopharyngeal and Oral Samples Compared to Other 502 Variants of Concern and Impact on Diagnostic Testing Strategy Vaccine Dose Persistence of 508 Immunogenicity after Seven Covid-19 Vaccines Given as Third Dose Boosters Following 509 Two Doses of Chadox1 Ncov-19 or Bnt162b2 in the Uk: Three Month Analyses of the 510 Epub 20220409 Safety and 512 Efficacy of a Third Dose of Bnt162b2 Covid-19 Vaccine Protection 515 with a Third Dose of Mrna Vaccine against Sars-Cov-2 Variants in Frontline Workers Efficient Recall of Omicron-Reactive B Cell Memory after a Third Dose of Sars-Cov-2 519 Epub 20220408 Existing Sars-Cov-2 Immunity Influences Potency, Breadth, and Durability of the Humoral 522 Response to Sars-Cov-2 Vaccination Bnt162b2 Vaccine against Hospital and Emergency Department Admissions Due to the 526 Omicron and Delta Variants in a Large Health System in the USA: A Test-Negative Case-527 Control Study Humoral and Cellular Immune Responses against Sars-Cov-2 6 Months after Full 531 Bnt162b2 Vaccination in Hospital Healthcare Workers Characteristics 534 Associated with Serological Covid-19 Vaccine Response and Durability in an Older 535 Population with Significant Comorbidity: The Danish Nationwide Enforce Study Vaccine Effectiveness against the Omicron (B.1.1.529) Variant Covid-19 Vaccine Effectiveness against Severe Disease from Sars-Cov-2 Omicron Ba.1 542 and Ba.2 Subvariants -Surveillance Results from Southern Sweden Effectiveness of Bnt162b2 546 Vaccine against Omicron Variant in South Africa Omicron Ba.1 and Ba.2 Variants Serum 552 Neutralization of Sars-Cov-2 Omicron Ba.1 and Ba.2 after Bnt162b2 Booster Vaccination Risk of Sars-Cov-2 Reinfection and Covid-19 Total 556 Population Cohort Study in Sweden Immune 559 Recall Improves Antibody Durability and Breadth to Sars-Cov-2 Variants Cov-2 Receptor-Binding Domain Antibody Evolution after Mrna Vaccination Affinity Maturation of Sars-Cov-2 Neutralizing Antibodies Confers Potency, Breadth, and 566 Resilience to Viral Escape Mutations Imprinted Sars-Cov-2-Specific Memory Lymphocytes Define Hybrid Immunity Escape from 572 Recognition of Sars-Cov-2 Variant Spike Epitopes but Overall Preservation of T Cell 573 Immunity Prior 576 Infection with Sars-Cov-2 Boosts and Broadens Ad26.Cov2.S Immunogenicity in a 577 Variant-Dependent Manner Cell Responses 580 to Sars-Cov-2 Spike Cross-Recognize Omicron Specific T Cells Cross-Recognize the Omicron Variant Mrna 586 Vaccines Induce Durable Immune Memory to Sars-Cov-2 and Variants of Concern A Guide to Vaccinology: From Basic Principles to New 589 Developments Immunological 592 Considerations for Covid-19 Vaccine Strategies